A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating the Efficacy and Safety of CNTO 1275 in the Treatment of Subjects With Moderate to Severe Plaque-Type Psoriasis

Trial Profile

A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating the Efficacy and Safety of CNTO 1275 in the Treatment of Subjects With Moderate to Severe Plaque-Type Psoriasis

Completed
Phase of Trial: Phase III

Latest Information Update: 01 Dec 2016

At a glance

  • Drugs Ustekinumab (Primary)
  • Indications Plaque psoriasis
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Acronyms PHOENIX-1
  • Sponsors Centocor
  • Most Recent Events

    • 08 Mar 2016 Results of pooled analysis assessing the association between HLA-Cw6 status and efficacy of ustekinumab from Phoenix 1, Phoenix 2, and ACCEPT studies, presented at the 74th Annual Meeting of the American Academy of Dermatology.
    • 28 Sep 2012 Safety data from a pooled analysis of this and the PHOENIX-2 and ACCEPT trials were presented at the 21st European Academy of Dermatology and Venereology (EADV) congress in late September 2012.
    • 22 Feb 2012 Long-term results published in the British Journal of Dermatology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top